|
|
 |
|
Viewing report
|
|
|
|
Preclinical Models: Innovative Solutions to Accelerate Drug Discovery and Development
Business Insights, Feb 2010, Pages: 131
Preclinical models are developed to test lead compounds for toxicity and efficacy. They are valuable tools to minimize development costs and reduce failures prior to commencement of human trials. Problems with traditional animal models such as cost, ethics, and suitability has prompted researchers to develop new models and systems to overcome such disadvantages. Alternative approaches include new vertebrate, nonvertebrate, computer-based and imaging models that offer new perspectives and utility to aid the drug discovery and development process.
This report explores novel preclinical models that show promise to expedite and improve the target validation and lead optimization timeline and discusses the various advantages and disadvantages of ADMET screening technologies to provide insight on which models or systems may enhance the R&D function of pharmaceutical and biotechnology organisations.
Additionally, the report provides an outlook for preclinical testing over the next decade and how pharmaceutical companies may need to adjust to new systems and models to improve their efficiencies. It uniquely focuses on more than 60 companies that are involved in using or developing ADMET technologies to advance preclinical research and provides an update on recent company activities and developments where new models and systems are employed to accelerate the discovery and development process.
Key features of this report
- Analysis of current developments in preclinical ADMET research for drug discovery and development
- Evaluation of the drivers behind innovation in preclinical research.
- Identifies the current trends in ADMET research and how technology companies are developing new models to improve and accelerate discovery and development.
- Analysis of current in-vivo, in-vitro, in-silico, and systems biology models that are advancing toxicity prediction in early drug discovery.
Scope of this report
- Understand the basis to ADMET testing and why it is a necessary and important component of preclinical research
- Up-to-date information on the preclinical models and systems currently used in drug discovery and development.
- Evaluation of the key recent developments and activities of companies who are developing and licensing new ADMET technologies.
- Identifies existing models and how new ones are being developed to improve productivity and knowledge.
Key Market Issues
- Established preclinical models correlate poorly with human in-vivo biological responses therefore innovation is needed to approximate more accurately the human response.
- Technology and software providers are developing novel models to expand the ADMET market in order to accelerate drug discovery and development.
- In-vivo, in-vitro, and in-silico models are increasingly becoming more sophisticated and a push for integration is creating demand for highly efficient centralized platforms to expedite predictive ADMET insight.
Key findings from this report
- Innovation in preclinical research is rapidly changing the landscape for ADMET testing and new models are accelerating decision-making in discovery and development.
- Novel in-vivo, in-vitro, in-silico and systems biology models are accelerating the discovery and development timeline for pharmaceutical companies.
- Demand to reduce in-vivo whole-organism ADMET testing has stimulated in-silico research but novel animal models and in-vitro screens will be needed to complement and correlate in-silico prediction.
- New vertebrate and invertebrate whole organism preclinical models include humanized rodents and zebrafish that provide disease-state environments, which better predict biological responses to investigational compounds.
Key questions answered
- What are preclinical models and how are they important to the pharmaceutical industry?
- What are the advantages and disadvantages of preclinical models in ADMET screening?
- What are the innovations in preclinical models?
- What are the trends in preclinical research?
- How are in-vivo, in-vitro, in-silico and systems biology models being developed for ADMET?
- How are companies building ADMET capabilities?
Customers who bought this item also bought
Early Stage Drug Safety Strategies and Risk Management: Maximizing Opportunities Towards Achieving Clinical Success
Accelerating Lead Generation: Emerging Technologies and Strategies
Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies
Predictive ADME and Toxicology Strategies: Challenges and Opportunities for In Vivo, In Vitro and In Silico Predictive Technologies
Systems Biology in Biotech and Pharma: A New Paradigm for Innovation
Personalized Medicine - Scientific and Commercial Aspects
Developments in Early-Stage Toxicity Prediction
ADMET for Medicinal Chemists: A Practical Guide
Lead Generation Strategies and Technologies in Drug Development - Emerging Techniques Such as Antisense Technology Will Allow Innovators to Minimize Costs
Alzheimer Disease - New Drugs, Markets and Companies
|
|
|
|
